Tandem Diabetes Care Inc
TNDM Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 23, 2026
$17.43
KIRA · Stoqly’s AI analyst, in plain words
- Tandem Diabetes Care Inc had $1.0B of revenue in fiscal 2025, up 7.9% on the year before. Over five years, revenue changed +15.3% a year on average.
- Its operating margin was −18.5%, down 7.9 pts: of every 100 in sales, about −18 is left after running the business.
- Tandem Diabetes Care Inc lost $205M in fiscal 2025.
- Free cash flow was −$29.7M in fiscal 2025, −2.9% of revenue.
- Tandem Diabetes Care Inc returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 2.8%.
- Tandem Diabetes Care Inc owes $17.4M more than it holds in cash.
Market cap
$1.2B
P/E
—
Revenue
$1.0B
Net income
−$205M
Free cash flow
−$29.7M
Operating margin
−18.5%
Tandem Diabetes Care Inc in 30 seconds · fiscal 2025
Are sales growing?
+7.9%
Yes. Sales grew 7.9% last year.
Does it make a profit?
−20.2%
No. It lost money last year.
Does profit turn into cash?
−2.9%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 9
Mixed. It passes 4 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Tandem Diabetes Care Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 19, 2026
- Legal name
- TANDEM DIABETES CARE INC
- CIK
- 0001438133
Tandem Diabetes Care Inc · TNDM
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $703M | $801M | $748M | $940M | $1.0B |
| Revenue growth | 40.9% | 14.0% | −6.7% | 25.7% | 7.9% |
| Gross margin | 53.5% | 51.5% | 49.2% | 52.1% | 53.8% |
| Operating margin | 3.2% | −11.6% | −31.2% | −10.5% | −18.5% |
| Net income | $15.6M | −$94.6M | −$223M | −$96.0M | −$205M |
| Net margin | 2.2% | −11.8% | −29.8% | −10.2% | −20.2% |
| Diluted EPS | $0.24 | −$1.47 | −$3.43 | −$1.47 | −$3.04 |
| Cash | |||||
| Cash from operations | $111M | $50.5M | −$31.8M | $24.2M | −$9.7M |
| Capital expenditure | $14.2M | $34.1M | $26.8M | $19.2M | $19.9M |
| Free cash flow | $97.2M | $16.4M | −$58.6M | $5.0M | −$29.7M |
| FCF margin | 13.8% | 2.0% | −7.8% | 0.5% | −2.9% |
| Share buybacks | — | $0.0M | $0.0M | $30.0M | $0.0M |
| Share count change | 5.5% | −0.3% | 1.3% | 0.7% | 2.8% |
| Debt and strength | |||||
| Cash and short-term investments | $624M | $617M | $468M | $438M | $293M |
| Debt incl. finance leases | — | — | $285M | $349M | $310M |
| Shareholders' equity | $433M | $440M | $314M | $263M | $155M |
| Current ratio | 6.2x | 5.1x | 3.8x | 2.9x | 2.5x |
| Interest coverage | — | −15.0x | −23.6x | −13.4x | −23.7x |
| Returns and quality | |||||
| Return on capital | — | — | −140.9% | −45.1% | −85.7% |
| Return on equity | 3.9% | −21.7% | −59.1% | −33.3% | −97.9% |
| Return on tangible equity | 3.6% | −21.7% | −71.6% | −36.6% | −142.7% |
| Piotroski F-score | 7 | 3 | 2 | 5 | 4 |
| Altman Z'' | 3.8 | 2.2 | −0.6 | −0.6 | −3.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
1 insider
Of sales under plans
100%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Tandem Diabetes Care Inc · TNDM
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $17.43 a share, the company is worth $1.2B.
Source: SEC EDGAR XBRL filings (CIK 0001438133). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.